首页> 外文期刊>The Journal of Urology >Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer.
【24h】

Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer.

机译:无细胞循环DNA:对睾丸生殖细胞癌患者的诊断价值。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: Increased levels of cell-free circulating DNA have been described in various malignancies as a diagnostic and prognostic biomarker. We analyzed the significance of cell-free DNA in patients with testicular cancer. MATERIALS AND METHODS: Cell-free DNA was isolated from the serum of 74 patients with testicular cancer, including 39 with seminoma and 35 with nonseminoma, and 35 healthy individuals. Real-time polymerase chain reaction was used to quantify a 106, a 193 and a 384 actin-beta DNA fragment. DNA integrity is expressed as the ratio of large (193 or 384 bp) to short (106 bp) DNA fragments. RESULTS: Actin-beta-106/193/384 fragment levels were significantly increased in patients with cancer compared to those in healthy individuals (each p <0.001). DNA integrity was significantly decreased in patients with cancer (p <0.001). Cell-free DNA fragment levels were not different when comparing patients with nonseminoma and seminoma (p >0.24). ROC analysis demonstrated that cell-free DNA levels distinguished patients with cancer from healthy individuals with 87% sensitivity and 97% specificity. Even in 31 patients in whom the established serum tumor markers alpha-fetoprotein, human chorionic gonadotropin, placental alkaline phosphatase and lactate dehydrogenase were normal cell-free DNA levels allowed us to distinguish between patients with cancer and healthy individuals with 84% sensitivity and 97% specificity. Cell-free DNA levels were more frequently increased in patients with clinical stage 3 than in patients with stage 1 or 2 disease (p <0.046). CONCLUSIONS: Cell-free DNA levels are increased in patients with testicular cancer and they allow the accurate discrimination of healthy individuals. The high sensitivity of cell-free DNA could facilitate the management of testicular cancer, especially in patients with conventional tumor markers that are not increased.
机译:目的:无细胞循环DNA水平的升高已在各种恶性肿瘤中被描述为诊断和预后的生物标志物。我们分析了无细胞DNA在睾丸癌患者中的意义。材料与方法:从74例睾丸癌患者的血清中分离出无细胞DNA,包括39例精原细胞瘤,35例非精原细胞瘤和35例健康个体。实时聚合酶链反应用于定量106、193和384肌动蛋白βDNA片段。 DNA完整性表示为大片段(193或384 bp)与短片段(106 bp)的比率。结果:与健康个体相比,癌症患者的肌动蛋白-β-106/ 193/384片段水平显着增加(每个p <0.001)。癌症患者的DNA完整性显着降低(p <0.001)。比较非精原细胞瘤和精原细胞瘤患者的无细胞DNA片段水平无差异(p> 0.24)。 ROC分析表明,无细胞DNA水平以87%的敏感性和97%的特异性将癌症患者与健康个体区分开。即使在31例血清肿瘤标志物甲胎蛋白,人绒毛膜促性腺激素,胎盘碱性磷酸酶和乳酸脱氢酶水平正常的患者中,无细胞DNA水平也使我们能够以84%的敏感性和97%的敏感性区分癌症患者和健康个体特异性。临床3期患者的无细胞DNA水平比1期或2期疾病的患者更频繁地升高(p <0.046)。结论:睾丸癌患者的无细胞DNA水平升高,可准确区分健康个体。无细胞DNA的高敏感性可以促进睾丸癌的治疗,特别是对于那些常规肿瘤标志物没有增加的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号